Lower muscle volume, and more fat stored in the muscle, are seen linked to higher risk for disease and comorbidities.

Tildrakizumab is an interleukin-23 antagonist approved under the brand name Ilumya for the treatment of plaque psoriasis.

In July 2025, Janssen Research & Development LLC conducted a study is to evaluate the efficacy of icotrokinra compared to ...

Patients with psoriatic arthritis with a family history of psoriatic disease are diagnosed with psoriasis and psoriatic ...

Both men and women with psoriasis are equally at risk for developing psoriatic arthritis (PsA)—a chronic inflammatory ...

Self-care methods for psoriatic arthritis (PsA) include staying active with gentle exercises, getting enough sleep, and ...

Researchers have found in a new research that deucravacitinib significantly improves joint pain and musculoskeletal symptoms ...

Many people with psoriatic arthritis will experience symptoms in their feet. This can lead to swollen toes, pitted nails, ...

Dealing with the itchy, scaly patches that come with psoriasis is difficult enough. But having psoriasis puts you at risk of developing psoriatic arthritis, an inflammatory condition that impacts the ...

With new systemic treatments now available for psoriatic disease, questions remain on the comparable efficacy and safety of these therapies.

Sun Pharma’s INSPIRE-1 and INSPIRE-2 studies met their primary endpoint at Week 24, with Ilumya 100 mg demonstrating superior ...

Sun Pharmaceutical Industries announced that its psoriasis drug Ilumya (tildrakizumab 100 mg) delivered positive results in ...